By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Spectrum Pharmaceuticals, Inc. 

157 Technology Drive

Irvine  California  92618  U.S.A.
Phone: 949-788-6700 Fax: 949-788-6706




Company News
Spectrum Pharma (SPPI) Submits Phase 2 Breast Cancer Protocol To FDA As Part Of An Investigational New Drug (IND) Application For Poziotinib 11/20/2015 11:07:02 AM
Spectrum Pharma (SPPI) Divests Rights To ZEVALIN (ibritumomab tiuxetan) In Japan And Select Other Ex-US Countries To Mundipharma AG 11/18/2015 11:19:41 AM
Eagle Pharmaceuticals (EGRX) And Spectrum Pharma (SPPI) Announce Co-Promotion Agreement 11/5/2015 1:01:40 PM
Spectrum Pharma (SPPI) Reports Third Quarter 2015 Financial Results and Pipeline Update 11/5/2015 12:39:18 PM
Spectrum Pharma (SPPI) Announces Third Quarter 2015 Financial Results Teleconference And Webcast 11/2/2015 9:04:01 AM
Spectrum Pharma (SPPI) Initiates Apaziquone Pivotal Trial For The Treatment Of Non-Muscle Invasive Bladder Cancer (NMIBC) Following SPA Agreement 10/26/2015 7:48:20 AM
FDA Declines to Approve Spectrum Pharma (SPPI)'s Evomela for Injection 10/23/2015 6:09:46 AM
Spectrum Pharmaceuticals, Inc. (SPPI) To Present Corporate Update At The Rodman & Renshaw 17th Annual Global Investment Conference On September 10th 9/3/2015 10:02:33 AM
Spectrum Pharmaceuticals, Inc. (SPPI) Announces Publication Of Pivotal EVOMELA (Melphalan Hydrochloride) For Injection Data In The Biology Of Blood And Marrow Transplantation Journal 9/2/2015 10:41:38 AM
Spectrum Pharmaceuticals, Inc. (SPPI) Announces Agreement With FDA On The Special Protocol Assessment (SPA) For The Upcoming Apaziquone Phase 3 Trial In Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) 8/17/2015 10:55:07 AM